The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II trial of nivolumab (NIVO) + palbociclib (PAL) + anastrozole (ANA) in postmenopausal women and men with estrogen receptor (ER)+/human epidermal growth factor 2 (HER2)- primary breast cancer (BC): CheckMate 7A8.
 
Sara M. Tolaney
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; Celldex; Eisai; G1 Therapeutics; Genentech; Immunomedics; Lilly; Merck; NanoString Technologies; Nektar; Novartis; Odonate Therapeutics; Paxman; Pfizer; Puma Biotechnology; Sanofi; Seagen; Silverback Therapeutics
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Cyclacel (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Immunomedics (Inst); Lilly (Inst); Merck (Inst); NanoString Technologies (Inst); Nektar (Inst); Novartis (Inst); Odonate Therapeutics (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Celldex; Eisai; Genentech/Roche; Immunomedics; Lilly; Merck; NanoString Technologies; Nektar; Novartis; Pfizer; Puma Biotechnology
 
Guy Jerusalem
Honoraria - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Lilly; Novartis; Pfizer; Roche
Research Funding - Novartis (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bristol-Myers Squibb; Lilly; Medimmune; Merck; Novartis; Pfizer; Roche
 
Roberto Salgado
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Roche
Research Funding - Merck; Puma Biotechnology
Travel, Accommodations, Expenses - Merck; Roche
 
Xiaochun Liu
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Tian Chen
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
Patents, Royalties, Other Intellectual Property - COMBINATION THERAPY WITH ANTI-IL-8 ANTIBODIES AND ANTI-PD-1 ANTIBODIES FOR TREATING CANCER
 
Hongxia Zhang
Employment - Bristol-Myers Squibb
 
Mustimbo Roberts
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Dimitrios Zardavas
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Aleix Prat
Employment - Novartis (I)
Honoraria - Amgen; Daiichi Sankyo; Lilly; MSD Oncology; Novartis; Pfizer; Roche
Consulting or Advisory Role - Abbvie; Amgen; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Daiichi Sankyo; NanoString Technologies (Inst); Novartis; Oncolytics; Pfizer; Puma Biotechnology; Roche
Research Funding - Incyte (Inst); Novartis (Inst); Puma Biotechnology (Inst); Puma Biotechnology (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - PCT/EP2016/080056: HER2 AS A PREDICTOR OF RESPONSE TO DUAL HER2 BLOCKADE IN THE ABSENCE OF CYTOTOXIC THERAPY; WO/2018/096191. Chemoendocrine score (CES) Based on PAM50 for breast cancer with positive hormone receptors with an intermediate risk of recurrence
Travel, Accommodations, Expenses - Daiichi Sankyo
Other Relationship - Oncolytics; Peptomyc